ArticleDiabetology & metabolic syndrome2026
Development and temporal external validation of a high-specificity XGBoost rule-in model for diabetes in middle-aged and older Korean adults.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Early identification of diabetes in older adults is essential for preventing complications, yet many high‑risk individuals remain undetected in community settings. Using recent cycles of the nationally representative Korea National Health and Nutrition Examination Survey (KNHANES 2020-2023), we developed and temporally validated an Extreme Gradient Boosting (XGBoost) model to rule-in diabetes among Korean adults aged ≥ 50 years. Candidate predictors included sociodemographic factors, health behaviors, anthropometric indices, blood pressure, medical history, and simple laboratory markers. Data from 2020 to 2022 were used for model development, with the 2023 cycle reserved as a temporal external validation cohort. We prespecified a high‑specificity rule‑in threshold based on the development cohort and evaluated discrimination (area under the receiver operating characteristic curve (AUROC) and average precision), calibration, Brier score, classification metrics, decision‑curve net benefit, and Shapley additive explanation (SHAP) values. In temporal external validation, the XGBoost model demonstrated robust performance (AUROC 0.868; average precision 0.646; Brier score 0.101) and achieved high rule-in accuracy (0.866), specificity (97.3%), positive predictive value (76.7%), and F1-score (0.521) at the prespecified threshold. Compared with logistic regression and random forest, the model showed superior rule-in performance and performed comparably to Light Gradient Boosting Machine (LightGBM), a gradient boosting framework based on decision tree ensembles, in terms of specificity and positive predictive value, while intentionally accepting reduced sensitivity consistent with a high-specificity design. SHAP analyses identified urine creatinine, urine specific gravity, urine albumin, total cholesterol and other lipids, body mass index, waist circumference, and a history of hypertension and dyslipidemia as major contributors to model predictions. These findings indicate that an XGBoost-based rule-in model using routinely collected survey variables can efficiently identify older Korean adults with a high probability of diabetes and may serve as a practical decision-support tool for prioritizing confirmatory testing and targeted screening in community settings with limited resources.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.